Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00695955 · ClinicalTrials.gov registry record · Phase 3
One-Year Safety and Tolerability Study of Azilsartan Medoxomil in Participants With Essential Hypertension
A Phase 3 study, sponsored by Takeda.
- Completed
- Registry status
- Phase 3
- Development phase
- 669
- Enrollment target
NCT00695955 is a Phase 3 study that has completed, run by Takeda. The registered enrollment target is 669 participants.
The verdict
NCT00695955, a Phase 3 study, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 669 participants
- Enrollment target
Study Summary
This purpose of this study is to evaluate the long-term safety and tolerability of azilsartan medoxomil in individuals with essential hypertension.
Interventions
- DRUG Azilsartan medoxomil with or without add-on chlorthalidone
- DRUG Azilsartan medoxomil with or without add-on hydrochlorothiazide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 669 participants |
| Start Date | 2007-06 |
| Est. Completion | 2010-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00695955
The ClinicalTrials.gov registry entry for NCT00695955 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 669 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Azilsartan medoxomil with or without add-on chlorthalidone is the first listed.
NCT00695955 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00695955 about?
NCT00695955 is a clinical study titled "One-Year Safety and Tolerability Study of Azilsartan Medoxomil in Participants With Essential Hypertension". This purpose of this study is to evaluate the long-term safety and tolerability of azilsartan medoxomil in individuals with essential hypertension.
What is the current status of trial NCT00695955?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 669 participants. The study started on 2007-06. Estimated completion is 2010-05.
What interventions are being tested in trial NCT00695955?
The interventions under investigation include: Azilsartan medoxomil with or without add-on chlorthalidone (DRUG), Azilsartan medoxomil with or without add-on hydrochlorothiazide (DRUG).
Who is sponsoring clinical trial NCT00695955?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.